Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

SEC Filings

10-K
PACIRA PHARMACEUTICALS, INC. filed this Form 10-K on 03/01/2017
Entire Document
 << Previous Page | Next Page >>

PACIRA PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
 
Year Ended December 31,
 
2016
 
2015
 
2014
Operating activities:
 
 
 
 
 
Net income (loss)
$
(37,949
)
 
$
1,856

 
$
(13,716
)
Adjustments to reconcile net income (loss) to net cash provided by
operating activities:
 
 
 
 
 
Depreciation of fixed assets and amortization of intangibles
12,919

 
11,475

 
10,035

Amortization of unfavorable lease obligation and debt issuance costs
479

 
481

 
487

Amortization of debt discount
4,088

 
4,102

 
4,139

Loss on disposal of fixed assets
389

 
6

 
158

Loss on early extinguishment of debt

 
52

 

Stock-based compensation
31,248

 
33,368

 
24,822

Changes in operating assets and liabilities:
 
 
 
 
 
Restricted cash

 
1,509

 
124

Accounts receivable, net
(4,082
)
 
(3,489
)
 
(7,776
)
Inventories, net
30,367

 
(32,382
)
 
(13,706
)
Prepaid expenses and other assets
(3,377
)
 
(2,007
)
 
(1,621
)
Accounts payable, accrued expenses and income taxes payable
710

 
8,966

 
15,349

Royalty interest obligation

 
(276
)
 
(970
)
Other liabilities
87

 
5,786

 
2,526

Deferred revenue
(1,426
)
 
(1,426
)
 
6,713

Net cash provided by operating activities
33,453

 
28,021

 
26,564

Investing activities:
 
 
 
 
 
Purchases of fixed assets
(24,709
)
 
(40,295
)
 
(22,984
)
Purchases of investments
(192,815
)
 
(189,082
)
 
(164,303
)
Sales of investments
171,627

 
217,240

 
80,286

Payment of contingent consideration
(15,857
)
 
(7,119
)
 
(13,433
)
Net cash used in investing activities
(61,754
)
 
(19,256
)
 
(120,434
)
Financing activities:
 
 
 
 
 
Proceeds from follow-on public offering, net

 

 
110,452

Proceeds from exercise of stock options and warrants
5,770

 
10,073

 
7,239

Proceeds from shares issued under employee stock purchase plan
1,495

 
2,093

 
1,184

Conversion of principal and equity component of convertible senior notes
(4
)
 
(1,467
)
 

Net cash provided by financing activities
7,261

 
10,699

 
118,875

Net increase (decrease) in cash and cash equivalents
(21,040
)
 
19,464

 
25,005

Cash and cash equivalents, beginning of year
56,984

 
37,520

 
12,515

Cash and cash equivalents, end of year
$
35,944

 
$
56,984

 
$
37,520

Supplemental cash flow information:
 
 
 
 
 
Cash paid for interest, including royalty interest obligation
$
3,852

 
$
4,224

 
$
5,193

Cash paid for income taxes, net of refunds
$
247

 
$
195

 
$
34

Non-cash investing and financing activities:
 
 
 
 
 
Issuance of stock from conversion of convertible senior notes
$

 
$
3,929

 
$

Net increase (decrease) in accrued fixed assets
$
(789
)
 
$
1,393

 
$
(1,095
)
See accompanying notes to consolidated financial statements.

F- 8

 << Previous Page | Next Page >>

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...